CHF290.50
2.09% yesterday
SIX Swiss Exchange, Mar 31, 05:30 pm CET
ISIN
CH0012032048
Symbol
ROG
Index
Sector
Industry

Roche Stock price

CHF290.50
-8.70 2.91% 1M
+19.90 7.35% 6M
+35.00 13.70% YTD
+60.80 26.47% 1Y
-75.95 20.73% 3Y
-23.55 7.50% 5Y
+22.40 8.36% 10Y
SIX Swiss Exchange, Closing price Mon, Mar 31 2025
-6.20 2.09%
ISIN
CH0012032048
Symbol
ROG
Index
Sector
Industry

Key metrics

Market capitalization CHF236.00b
Enterprise Value CHF259.43b
P/E (TTM) P/E ratio 28.56
EV/FCF (TTM) EV/FCF 16.57
EV/Sales (TTM) EV/Sales 4.29
P/S ratio (TTM) P/S ratio 3.90
P/B ratio (TTM) P/B ratio 7.43
Dividend yield 3.27%
Last dividend (FY24) CHF9.70
Revenue growth (TTM) Revenue growth 3.03%
Revenue (TTM) Revenue CHF60.50b
EBIT (operating result TTM) EBIT CHF17.61b
Free Cash Flow (TTM) Free Cash Flow CHF15.65b
EPS (TTM) EPS CHF10.39
P/E forward 15.76
P/S forward 3.64
EV/Sales forward 4.00
Show more

Create a Free Account to create an Roche alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Roche Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Roche forecast:

13x Buy
50%
9x Hold
35%
4x Sell
15%

Analyst Opinions

26 Analysts have issued a Roche forecast:

Buy
50%
Hold
35%
Sell
15%

Financial data from Roche

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
60,495 60,495
3% 3%
100%
- Direct Costs 16,082 16,082
2% 2%
27%
44,413 44,413
4% 4%
73%
- Selling and Administrative Expenses 10,335 10,335
5% 5%
17%
- Research and Development Expense 13,042 13,042
1% 1%
22%
21,036 21,036
6% 6%
35%
- Depreciation and Amortization 3,423 3,423
1% 1%
6%
EBIT (Operating Income) EBIT 17,613 17,613
8% 8%
29%
Net Profit 8,277 8,277
28% 28%
14%

In millions CHF.

Don't miss a Thing! We will send you all news about Roche directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roche Stock News

Positive
Market Watch
about 8 hours ago
Investors and traders might focus on the reasons behind periods of decline or higher volatility in the stock market. But long-term investors have always needed to weather stock-market storms, regardless of political trends.
Neutral
GlobeNewsWire
6 days ago
Basel, 25 March 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders had approved all proposals of the Board of Directors at its Annual General Meeting. The 616 shareholders in attendance, who represented 77.03% of the total 106,691,000 shares, approved the Annual Financial Statements and Consolidated Financial Statements for 2024, the Remuneration Report and the Sust...
Negative
Reuters
13 days ago
Swiss drugmaker Roche has abandoned global targets for a more diverse workforce to avoid penalties from recent U.S. executive orders, the latest in a slew of companies to do so.
More Roche News

Company Profile

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Thomas Schinecker
Employees 103,249
Founded 1896
Website www.roche.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today